RecruitingNot ApplicableNCT06581471

The TRICURE EU Pivotal Study

The TRICURE EU PIVOTAL TRiCares Topaz Transcatheter TRICUspid Heart Valve REplacement System EUropean PIVOTAL Study

Sponsor

TRiCares

Enrollment

80 participants

Start Date

Aug 29, 2024

Study Type

INTERVENTIONAL

Conditions

Cardiovascular Diseases Heart Valve Disease Tricuspid Valve Regurgitation

Summary

Prospective, multi-center study to assess safety and performance of the TRiCares Topaz Tricuspid Valve Replacement System

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called Transcatheter Tricuspid Valve Replacement for people with cardiovascular diseases, heart valve disease, and other related conditions. The study is currently recruiting participants at 8 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICETranscatheter Tricuspid Valve Replacement

Replacement of the tricuspid valve through a transcatheter approach

Locations(8)

Algemeen Stedelijk Ziekenhuis

Aalst, Belgium

ZNA Middelheim

Antwerp, Belgium

UZ Brussel

Brussels, Belgium

Cliniques Universitaires Saint-Luc UCL

Brussels, Belgium

Centre hospitalier universitaire CHU de Liège

Liège, Belgium

AZ Delta

Roeselare, Belgium

University Medical Center of the Johannes Gutenberg University Mainz

Mainz, Germany

Ludwig Maximilian University Hospital

Munich, Germany

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06581471

Related Trials

Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging

NCT076130991 location

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

NCT070644731149 locations

Diabetes and Heart Disease Risk in Blacks

NCT000018531 location

Cerebrovascular Health and Resilience in Midlife

NCT060293481 location

JOint Use of Database to Identify Risk Factors of CARDio-vascular Toxicity Induced by Immune Checkpoint Inhibitors

NCT04294771